Princeton Capital Management LLC Invests $4.04 Million in Astrazeneca Plc $AZN

Princeton Capital Management LLC purchased a new stake in Astrazeneca Plc (NYSE:AZN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 23,018 shares of the company’s stock, valued at approximately $4,040,000. Astrazeneca makes up about 1.0% of Princeton Capital Management LLC’s portfolio, making the stock its 18th biggest holding.

Several other large investors have also added to or reduced their stakes in AZN. Bank of Montreal Can lifted its position in Astrazeneca by 344.6% in the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after acquiring an additional 2,695,793 shares in the last quarter. Holocene Advisors LP increased its stake in Astrazeneca by 41.8% in the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after buying an additional 1,807,565 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its stake in Astrazeneca by 11,190.9% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock valued at $317,107,000 after buying an additional 1,790,874 shares during the last quarter. Raymond James Financial Inc. increased its stake in Astrazeneca by 64.8% in the 2nd quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock valued at $264,373,000 after buying an additional 1,487,662 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after buying an additional 1,461,786 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Up 1.5%

Shares of NYSE:AZN opened at $187.50 on Thursday. The firm has a fifty day moving average price of $191.82 and a two-hundred day moving average price of $182.58. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The company has a market cap of $290.79 billion, a price-to-earnings ratio of 28.15, a PEG ratio of 1.52 and a beta of 0.26.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Analysts anticipate that Astrazeneca Plc will post 10.25 EPS for the current fiscal year.

Analysts Set New Price Targets

AZN has been the subject of several analyst reports. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Barclays upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings initiated coverage on shares of Astrazeneca in a research note on Wednesday, March 11th. They issued a “buy (b)” rating for the company. Finally, Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Astrazeneca presently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.